When various cytokines that contribute to cancer cachexia such as transforming growth factor-β, IL-6, and tumor necrosis factor-alpha are inhibited, bone mineral density loss is attenuated, most likely by preventing full differentiation of osteoclasts through the receptor activator of nuclear factor-κB receptor activator of nuclear factor-κB ligand (RANKL) pathway [27–29]. Here, IL6 is linked to cancer.